SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of...
Hence then, the article about abbisko therapeutics receives cde approval of breakthrough therapy designation for irpagratinib absk011 in the treatment of hcc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC )
Also on site :
- Thousands rally in Serbia as students continue fight against corruption
- 'SNL' Parodies 'Heated Rivalry' With Harry Potter Characters — And a Genius Cameo
- Iran’s Supreme Leader Ali Khamenei blames Trump for deadly protests